The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation without cell maturation impairment. CML pathogenesis is associated with the Ph chromosome leading to BCR-ABL tyrosine-kinase constitutive expression. The Ph negative MPN (PV, ET and PMF) are characterized by the mutation JAK2(V617F) of the JAK2 protein in the auto-inhibitory JH2 domain, which is found in most PV patients and in approximately half of ET and PMF patients. Considerable effort is being made to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients. In the present investigation, we evaluated the Death Inducer-Obliterator (DIDO) (variants DIDO 1, 2 and 3) levels in CML, PV, ET and PMF patients. Our data reported the DIDO 1, 2 and 3 differential expressions in Myeloproliferative Neoplasms.
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil.
Maria Gabriela
MG
Berzoti-Coelho
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil; Center for Cell-Based Therapy, Ribeirão Preto, Brazil. Electronic address: alineferreira591@gmail.com.
Aline Fernanda
AF
Ferreira
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil.
Natalia
N
de Souza Nunes
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil; Center for Cell-Based Therapy, Ribeirão Preto, Brazil.
Mariana Tomazini
MT
Pinto
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil; Center for Cell-Based Therapy, Ribeirão Preto, Brazil.
Maurício Cristiano Rocha
MC
Júnior
Center for Cell-Based Therapy, Ribeirão Preto, Brazil; Department of Internal Medicine, Ribeirão Preto Medical School, USP, Brazil.
Belinda Pinto
BP
Simões
Department of Immunology and Oncology, Centro Nacional de Biotecnología, Universidad Autónoma, Campus de Cantoblanco, Madrid, Spain.
Carlos
C
Martínez-A
Hospital de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brazil.
Elizabeth Xisto
EX
Souto
Center for Cell-Based Therapy, Ribeirão Preto, Brazil; Department of Internal Medicine, Ribeirão Preto Medical School, USP, Brazil.
Rodrigo Alexandre
RA
Panepucci
Center for Cell-Based Therapy, Ribeirão Preto, Brazil; Department of Internal Medicine, Ribeirão Preto Medical School, USP, Brazil.
Dimas Tadeu
DT
Covas
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil; Center for Cell-Based Therapy, Ribeirão Preto, Brazil.
Simone
S
Kashima
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, USP, Brazil; Center for Cell-Based Therapy, Ribeirão Preto, Brazil.
Fabíola Attié
FA
Castro
D000328:Adult; D000368:Aged; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D014644:Genetic Variation; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000473:pathology*; D011087:Polycythemia Vera; D055728:Primary Myelofibrosis; D013920:Thrombocythemia, Essential; D055815:Young Adult
C518584:DIDO1 protein, human; D004268:DNA-Binding Proteins; C507924:JAK2 protein, human; D053614:Janus Kinase 2
Apoptosis; BCR-ABL1; DIDO; JAK2(V617F); Myeloproliferative Neoplasms